Page 9 - தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Zydus Cadila s COVID-19 vaccine for children above 12 years likely to get DCGI nod this week
india.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from india.com Daily Mail and Mail on Sunday newspapers.
DGCI may approve Zydus Cadila s COVID-19 vaccine for children above 12 years this week
freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.
Moderna rep admits everyone is part of huge experiment -- Society s Child -- Sott net
sott.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sott.net Daily Mail and Mail on Sunday newspapers.
Covaxin has 77.8% efficacy against Covid
Agencies / Updated: Jul 4, 2021, 06:00 IST
Bharat Biotech concludes final analysis from phase 3 clinical trials
Efficacy analysis demonstrates
covid-19, through evaluation of 130 confirmed cases, with 24 observed in the
vaccine group versus 106 in the placebo group.
Bharat Biotech has concluded final analysis for Covaxin efficacy from Phase 3 clinical trials. Efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19. Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects feeling serious adverse events.
The data demonstrates 63.6 per cent protection against asymptomatic COVID-19 and efficacy data demonstrates 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant.
Representative Image
Bharat Biotech releases Phase 3 trial results of Covaxin, claims vaccine efficacy of 78.8 pc against COVID-19 By Sahil Pandey | Updated: Jul 03, 2021 09:15 IST
Hyderabad (Telangana) [India], July 3 (ANI): Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it to be 77.8 per cent effective against COVID-19.
It also added that Covaxin gives 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant. Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19, the company said.